| Product Unit Size | Cost | Quantity | Stock |
|---|
Volitinib is an inhibitor of c-Met. It shows antitumor potential in models of gastric cancer. It is being investigated as a treatment for papillary renal cell carcinoma, where it has demonstrated an acceptable tolerability profile. TEST!!!!!!
| Cas No. | 1313725-88-0 |
|---|---|
| Purity | ≥98% |
| Formula | C17H15N9 |
| Formula Wt. | 345.37 |
| Chemical Name | Volitinib |
| IUPAC Name | 1-[(1S)-1-(Imidazo[1,2-a]pyridin-6-yl)ethyl]-6-(1-methyl-1H-pyrazol-4-yl)-1H-[1,2,3]triazolo[4,5-b]pyrazine |
| Synonym | Savolitinib, HMPL 504, HMPL0-504, HMPL504, AZD-6094, AZD 6094, AZD6094 |
| Solubility | Insoluble in water. Solubility in DMSO - ~15 mg/mL. |
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
| MSDS | |
|---|---|
| Info Sheet |
Gavine P., Ren Y., et al. Volitinib, a potent and highly selective c-Met inhibitor, effectively blocks c-Met signaling and growth in c-MET amplified gastric cancer patient-derived tumor xenograft models. Mol Oncol. 9(1):323-33 (2015). PMID: 25248999.
Gan H., Millward M., et al. First-in-Human Phase I Study of the Selective MET Inhibitor, Savolitinib, in Patients with Advanced Solid Tumors: Safety, Pharmacokinetics and Anti-Tumor Activity. Clin Cancer Res. 2019. PMID: 30952639.